NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

Positive

AI Analysis

Summary

NovaGo Therapeutics closed a USD 30 million Series B financing round led by Neurimmune and Pureos to advance proof-of-concept studies in acute spinal cord injury. The round was complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.

Clinical Trial Data

Importance:5/10

Sentiment:

0.60

financingSeries Bspinal cord injurycapital raise

Read the original article

Published by PR Newswire Biotech on September 2, 2026 10:00 AM

Read Original